(p40)2-Fc reduces immune-inflammatory response through the activation of T cells in collagen induced arthritis mice
SCIE
SCOPUS
- Title
- (p40)2-Fc reduces immune-inflammatory response through the activation of T cells in collagen induced arthritis mice
- Authors
- Lee, SY; Lee, SH; Park, SJ; Kim, DJ; Kim, EK; Kim, JK; Yang, SH; Park, SH; Sung, YC; Kim, HY; Cho, ML
- Date Issued
- 2016-08
- Publisher
- Elsevier
- Abstract
- IL-12p40 homodimer, a natural antagonist of IL-12 and IL-23, performs an important role in the expression of proinflammatory cytokines that is essential for Th1 and Th17 immune responses. Here, we reveal the therapeutic and immunosuppressive effect of the IL-12p40 subunit ((p40)(2)-Fc) in an experimental autoimmune arthritis model. We hypothesized that (p40)(2)-Fc may reduce the inflammatory response and the activation of T cells. In this study, we intraperitoneally injected (p40)(2)-Fc into collagen induced arthritis (CIA) mice to identify whether (p40)(2)-Fc attenuates CIA severity. (p40)(2)-Fc reduced the development of CIA, joint inflammation and cartilage destruction. (p40)(2)-Fc also significantly decreased the concentration of serum immunoglobulin as well as the number of T cells and C II specific T cells. In addition, osteoclastogenesis in (p40)(2)-Fc treated mice was down-regulated compared to the mice treated with (p40)(2)-Fc control. We observed that (p40)(2)-Fc treatment alleviates arthritis in mice with CIA, reducing inflammation and osteoclast differentiation. These findings suggest that (p40)(2)-Fc can be a potential therapeutic approach for autoimmune arthritis. (C) 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/37489
- DOI
- 10.1016/J.IMLET.2016.05.013
- ISSN
- 0165-2478
- Article Type
- Article
- Citation
- Immunology Letters, vol. 176, page. 36 - 43, 2016-08
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.